Showing 7381-7390 of 8649 results for "".
- Nicox Granted New Patent for NCX 4251 in Japanhttps://modernod.com/news/nicox-granted-new-patent-for-ncx-4251-in-japan/2480657/Nicox SA announced that the Japanese Patent Office has granted a new patent expiring in 2040 covering the company’s product candidate NCX 4251. Patent JP.7021301 covers ophthalmic suspensions comprising a specific form of fluticasone p
- Nicox Granted Patent for NCX 470 in China, Extending Coverage to 2039https://modernod.com/news/nicox-granted-patent-for-ncx-470-in-china-extending-coverage-to-2039/2480655/Nicox SA announced that the Chinese National Intellectual Property Administration (CNIPA) has granted the company a formulation patent for NCX 470, its lead product candidate in development for patients with open-angle glaucoma or ocular hypertension, extending coverage in China to 2039. Wit
- Switzerland Eye Research Institute Publishes Breakthrough Case Report Using Light Exposure and Nutraceuticals for Treating Retinal Degenerationhttps://modernod.com/news/switzerland-eye-research-institute-publishes-breakthrough-case-report-using-light-exposure-and-nutraceuticals-for-treating-retinal-degeneration/2480653/Roberto Pinelli, MD, CEO of the Switzerland Eye Research Institute, announced the publication of a breakthrough paper in Archives Italiennes de Biologie. The report can be found here:
- Robert Califf Confirmed to Lead FDA for Second Timehttps://modernod.com/news/robert-califf-confirmed-to-lead-fda-for-second-time/2480645/The US Senate on Tuesday voted 50 to 46 in favor of confirming President Joe Biden nominee Robert Califf as commissioner of the FDA, a position he previously held under the Obama administration, according to a FiercePharma report.&
- Novartis Presents Positive Results From Three Phase 3 Trials of Beovu in DMEhttps://modernod.com/news/novartis-presented-positive-results-from-three-phase-3-trials-of-beovu-in-dme/2480638/At the Angiogenesis, Exudation, and Degeneration 2022 Virtual Meeting, Novartis presented additional positive results from three phase 3 trials of Beovu in DME, including results from patients dosed at up to 16-week intervals. This was the first detailed presentation of the year 2 results&nb
- Euclid Systems Expands US Commercial Teamhttps://modernod.com/news/euclid-systems-expands-us-commercial-team/2480634/Euclid Systems has announced the expansion of its US commercial team with the addition of Kellie Wesley, who has joined the com
- Ora Names Gustavo De Moraes, MD, PHD, Chief Medical Officerhttps://modernod.com/news/ora-names-gustavo-de-moraes-md-phd-chief-medical-officer/2480622/Ora announced that distinguished op
- Eyenovia Concludes Type A Meeting with FDA Related to MydCombi NDA Resubmissionhttps://modernod.com/news/eyenovia-concludes-type-a-meeting-with-fda-related-to-mydcombi-nda-resubmission/2480621/Eyenovia announced that the company successfully completed a meeting with the FDA related to the refiling of the NDA for MydCombi. On October 22, 2021, Eyenovia received a complete response letter (CRL) from the FDA stating that MydCombi, the co
- Maintaining Transparency: Study to Focus on Causes of Cataractshttps://modernod.com/news/maintaining-transparency-study-to-focus-on-causes-of-cataracts/2480616/Researchers at the University of Arizona College of Medicine – Tucson are leading a study to identify the biological mechanisms that cause cataracts in the hopes that new, nonsurgical treatments may be developed. Nicholas Delame
- My Vision Show 2022 to Preview "The Optiverse"https://modernod.com/news/my-vision-show-2022-to-preview-the-optiverse/2480615/My Vision Show, an optical virtual events production and media company, announced that My Vision Show Spring 2022,